Table 2.
Ongoing trials in BCC.
| Trial | Design | N' of patients | Indication | Intervention | ORR |
|---|---|---|---|---|---|
| NCT02690948 | Phase I/II | 16 | Advanced BCC | Participants who previously received vismodegib and subsequently progressed will receive pembrolizumab IV over 30 min on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. | ORR 44% |
| Participants who have not progressed while receiving vismodegib will receive pembrolizumab IV over 30 min on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. | ORR 29% | ||||
| NCT04679480 | Phase II | 20 | Advanced BCC | Cemiplimab administered as a flat 350 mg dose in every 3 weeks. Sonidegib 200 mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks starting from week 0. | |
| NCT03521830 | Phase II | 40 | laBCC/mBCC | Arm A: Nivolumab 480 mg IV every 4 weeks | |
| Arm B: Ipilimumab 1 mg/kg IV every 4 weeks for 4 doses | |||||
| Arm C: Relatlimab 480 mg IV q4wks | |||||
| NCT04323202 | Advanced BCC of head/neck | ||||
| NCT04799054 | Locally advanced/metastatic solid tumors | ||||
| NCT03458117 (20139157 T-VEC) | Locally advanced NMSC | ||||
| NCT02978625 | Advanced/refractory NMSC |